FRIDAY 15 SEPTEMBER
13:00 - 14:00 |
AbbvieDefining treatment strategies and comorbidities in JIA: Is there evidence for clinical consistency to optimize clinical practice? Chair: Angelo Ravelli (Italy) |
Banquet Hall
|
|
13:00 |
Welcome and introduction Angelo Ravelli (Italy) |
|
|
13:05 |
New paradigms in treat-to-target for JIA Angelo Ravelli (Italy) |
|
|
13:20 |
Seeking clinical consistency in the treatment of pediatric uveitis: What do the data tell us? Athimalaipet V. Ramanan (United Kingdom) |
|
|
13:35 |
Translating the data into real-world clinical practice Eric Fortin (Canada) |
|
|
13:50 |
Panel discussion All |
|
13:00 - 14:00 |
PfizerTreatment strategies in JIA: Delivering tomorrow Chair: Nicolino Ruperto (Italy)
|
Skalkotas Hall
|
|
13:00 |
Chairman’s welcome. Treatment of JIA today: PReSent, but correct? Nicolino Ruperto (Italy) |
|
|
13:10 |
What role can biosimilars play for our patients? Rieke Alten (Germany) |
|
|
13:30 |
Taking JIA into the future: novel therapies and new horizons Hermine Brunner (USA) |
|
|
13:50 |
Interactive audience discussion All |
|
|
14:00 |
Summary and close Nicolino Ruperto (Italy) |
|
13:00 - 14:00 |
Biomarin & Sanofi GenzymeWhen is JIA not JIA? A case-led discussion of its mimics Chair: Helen Foster (United Kingdom)
|
MC 3 Room
|
|
13:00 |
MPS in the rheumatology setting: an introduction Helen Foster (United Kingdom) |
|
|
13:10 |
Red-flag symptoms for MPS: when is JIA not JIA? Rolando Cimaz (Italy) |
|
|
13:30 |
Improving clinical outcomes of MPS patients: treatment and management strategies Julian Raiman (United Kingdom) |
|
|
13:50 |
Questions and summing up |
|
SATURDAY 16 SEPTEMBER
13:00 - 14:00 |
NovartisNovel approaches: Targeting IL-1ß The molecular signature of autoinflammatory disease Chair: Jasmin Kümmerle-Deschner (Germany) |
Banquet Hall
|
|
13:00 |
Living with systemic juvenile idiopathic arthritis and periodic fever syndromes: Perspectives from patients and their caregivers Nico Wulffraat (The Netherlands) |
|
|
13:15 |
New management strategies for Still’s disease Dirk Föll (Germany) and Eugen Feist (Germany) |
|
|
13:30 |
IL-1 Inhibition - Opportunities and challenges in the treatment of periodic fever syndromes Jasmin Kümmerle-Deschner (Germany) |
|
| 13:45 |
Panel Discussion/Q&A Jasmin Kümmerle-Deschner (Germany) |
|
13:00 - 14:00 |
ENZYVANTTherapy Refractory JIA? Think Farber Disease Chair: Seza Ozen (Turkey), Boris Hügle (Germany) |
Skalkotas Hall
|
| 13:00 |
Greeting and introduction Seza Ozen (Turkey) |
|
| 13:05 |
Sphingolipids in inflammation and Farber disease Edward H. Schuchman (USA) |
|
|
13:20 |
JIA or Farber disease? Clinical spectrum and differential diagnosis Boris Hügle (Germany) |
|
|
13:35 |
Cases from the Pediatric Rheumatology Clinic: Moderators: Seza Ozen (Turkey), Boris Hügle (Germany) 1. Severe phenotype - Onset in infancy Bo Magnusson (Sweden) 2. Moderate phenotype - Rapid progression Balahan Makay (Turkey) 3. Moderate phenotype - Slower progression Boris Hügle (Germany) |
|
|
13:55 |
Summary and conclusion Boris Hügle (Germany) |
|
